Trial Profile

Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Quizartinib (Primary) ; Cytarabine; Mitoxantrone
Indications Acute myeloid leukaemia
Focus Therapeutic Use
Acronyms Q-HAM

Most Recent Events

15 Sep 2023 Trial results will be reported via peer-reviewed journals and presented at conferences and scientific meetings.
15 Sep 2023 Trial design presented in the Trials
12 Sep 2022 Status changed from recruiting to discontinued as the study turned out no longer feasible

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com